

Lidocaine patch

Policy Number: C5168-A

CRITERIA EFFECTIVE DATES:

ORIGINAL EFFECTIVE DATE	LAST REVIEWED DATE	NEXT REVIEW DATE
03/2016	10/2018	10/2019
J CODE	TYPE OF CRITERIA	LAST P&T APPROVAL
NA	UPA	Q1

PRODUCTS AFFECTED: Lidoderm (lidocaine) patch, lidocaine pad/patch, Ztlido patch

DRUG CLASS: Local anesthetic- Topical

ROUTE OF ADMINISTRATION: Topical

PLACE OF SERVICE: Retail Pharmacy

AVAILABLE DOSAGE FORMS: Lidoderm (lidocaine) 5% patch, lidocaine 5% pad/patch, Ztlido 1.8% patch

FDA-APPROVED USES: indicated for relief of pain associated with post-herpetic neuralgia

COMPENDIAL APPROVED OFF-LABELED USES: None

COVERAGE CRITERIA: INITIAL AUTHORIZATION

DIAGNOSIS: post-herpetic neuralgia or cancer-related neuropathy

REQUIRED MEDICAL INFORMATION:**A. POST-HERPETIC NEURALGIA:**

1. Documentation of post-herpetic neuralgia or cancer-related neuropathy
AND
2. Inadequate response to a minimum one month trial of gabapentin at the maximum tolerated dose OR a contraindication to gabapentin.
AND
3. (a) Adequate trial and failure of preferred formulary agents (e.g OTC 4% patches).
OR
(b) Documented allergy or clinical contraindication to the formulary agents.

DURATION OF APPROVAL: Initial authorization: 3 months, Continuation of Therapy: 12 months

QUANTITY: 90 patches per 30 days

PRESCRIBER REQUIREMENTS: No requirement

AGE RESTRICTIONS: 5% patch: 18 years and over

GENDER: Male and female

CONTINUATION OF THERAPY:

A. FOR ALL INDICATIONS:

1. Documentation showing member has a positive response to therapy with improvement in pain systems.

CONTRAINDICATIONS/EXCLUSIONS/DISCONTINUATION:

All other uses are considered experimental/investigational and therefore, will follow Molina's Off-Label policy

OTHER SPECIAL CONSIDERATIONS:

OTC 4% patches are available and currently preferred – indicated only for pain relief at this time.

BACKGROUND: None

APPENDIX: None

REFERENCES:

1. National Comprehensive Cancer Network: Adult Cancer Pain V.1.2018. National Comprehensive Cancer Network. Fort Washington, PA. Available from:
https://www.nccn.org/professionals/physician_gls/PDF/pain.pdf
2. Lidoderm [package insert]. Malvern, PA: Endo Pharmaceuticals Inc; 2015.
3. Ztildo [package insert]. San Diego, CA: Scilex Pharmaceuticals; February 2018.